Sign In
Buy MLTX
$18.95
-0.180 (-0.94%)
At Close: Jul 02, 2026
MoonLake Immunotherapeutics' CFO Sells 39K Shares
10:14am, Friday, 03'rd Jul 2026
This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
03:04pm, Friday, 26'th Jun 2026
MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and strong long-term data for sonelokimab in hidradenitis suppurativa [HS]. MLTX expects to submit a BLA for
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
07:49pm, Wednesday, 24'th Jun 2026
It aims to raise up to $200 million in the offering. This will support its efforts to bring its top drug candidate to market.
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
11:08pm, Tuesday, 23'rd Jun 2026
ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin a
MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher
08:58am, Tuesday, 23'rd Jun 2026
MoonLake Immunotherapeutics is positioned for upside on differentiated efficacy and a large, underpenetrated hidradenitis suppurativa, or HS, market. Recent Phase 3 VELA data show sonelokimab achieves
MoonLake Immunotherapeutics Announces Proposed Public Offering
04:01pm, Monday, 22'nd Jun 2026
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin a
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
02:42pm, Monday, 22'nd Jun 2026
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
ZUG, Switzerland, June 21, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammato
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?
09:59pm, Thursday, 04'th Jun 2026
This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
11:44am, Monday, 11'th May 2026
MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday's trading session, trading higher as the company is reporting positive outcomes from its final pre-BLA meeting with the FDA regard
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
11:08am, Monday, 11'th May 2026
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April.
ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
10:17am, Saturday, 18'th Apr 2026
CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share. The sale represented 4.9% of Mr.
Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
04:05am, Thursday, 16'th Apr 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 shares of the firm's stock in a transaction on Friday, April 10th. The shares were sold at an average
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?
04:11am, Sunday, 12'th Apr 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report)'s share price traded down 6% during mid-day trading on Friday. The company traded as low as $18.36 and last traded at $18.2540. 326,345 sha
